Biogen Challenges USPTO Patent Term Adjustment Policy

Law360, New York (October 30, 2012, 5:55 PM EDT) -- Biogen Idec MA Inc. has become the latest company to challenge the U.S. Patent and Trademark Office's calculation of patent term adjustments, arguing in a suit filed in Virginia that the term of its patent on a compound used to treat neuronal dysfunction should be extended by 125 days.

Patent term adjustments are granted by the USPTO to compensate for delays in the examination process that cut into the effective term of the patent. In its complaint against the USPTO, filed Oct. 19, Biogen claimed that the office...
To view the full article, register now.